{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:13:24Z","timestamp":1789035204608,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903221"],"award-info":[{"award-number":["81903221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201371"],"award-info":[{"award-number":["81201371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ40986"],"award-info":[{"award-number":["2021JJ40986"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is no known effective treatment strategy to prevent relapses and avert permanent neurological sequelae in opsoclonus\u2013myoclonus syndrome (OMS). To describe the treatment strategy that reduced relapses and led to remission of OMS without permanent neurological sequelae.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This cross-sectional study was conducted at the Department of Pediatrics, Xiangya Hospital, Central South University. Patients diagnosed with OMS from January 2014 to July 2022 were enrolled. Exposures included treatment with multimodal immunotherapy. Main outcomes and measures included the OMS severity grading scale and DQ\/IQ scores. The clinical data was collected and analysed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the six recruited patients, three were (50.00%) males. The median age of onset was 15.50 months. Preceding manifestation was present in one patient and two cases had neuroblastoma. The mean duration from disease onset to the initiation of therapies was 1.86 months. The combinations of \u2265\u2009two therapies were used: combination of the intravenous immunoglobulin (IVIG) plus intravenous dexamethasone plus rituximab was used for three (50.00%) patients and the combination of the IVIG plus intravenous dexamethasone plus rituximab plus mycophenolate mofetil for one (16.67%) case. Besides, the combination of the intravenous methylprednisolone (IVMP, which was switched to intravenous dexamethasone later) plus rituximab was utilized for one (16.67%) case and the combination of the IVIG and IVMP for one (16.67%) patient. Total numbers of the therapies used comprised of dual therapy (33.33%), triple therapy (50.00%), and other multiple agents (16.67%). Besides, surgical resections were done for the cases with tumors. The disease course was monophasic for five cases and five cases achieved remission. OMS scores improved significantly at the end of follow up. Five (83.33%) patients did not have permanent neurological sequelae.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The combination of the intravenous dexamethasone plus IVIG plus rituximab for the OMS can reduce relapses and permanent neurological sequelae.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13052-025-01875-2","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:13:13Z","timestamp":1738948393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The utilization of the multimodal immunotherapy for the opsoclonus\u2013myoclonus syndrome can reduce relapses and permanent neurological sequelae"],"prefix":"10.1186","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-0424","authenticated-orcid":false,"given":"Fang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-9292","authenticated-orcid":false,"given":"Miriam","family":"Kessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-6308","authenticated-orcid":false,"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-9539","authenticated-orcid":false,"given":"Lifen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"1875_CR1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/B978-0-444-52910-7.00042-8","volume":"112","author":"M Pike","year":"2013","unstructured":"Pike M. Opsoclonus-Myoclonus syndrome. Handb Clin Neurol. 2013;112:1209\u201311.","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"1875_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.braindev.2014.10.010","volume":"37","author":"S Hasegawa","year":"2015","unstructured":"Hasegawa S, Matsushige T, Kajimoto M, Inoue H, Momonaka H, Oka M, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev. 2015;37(7):656\u201360.","journal-title":"Brain Dev"},{"issue":"2","key":"1875_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","volume":"14","author":"KK Pang","year":"2010","unstructured":"Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome\/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol EJPN off J Eur Paediatr Neurol Soc. 2010;14(2):156\u201361.","journal-title":"Eur J Paediatr Neurol EJPN off J Eur Paediatr Neurol Soc"},{"key":"1875_CR4","doi-asserted-by":"crossref","unstructured":"Rossor T, Yeh EA, Khakoo Y, Angelini P, Hemingway C, Irani SR et al. Diagnosis and management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Neurol Neuroimmunol Neuroinflammation. 2022;9(3).","DOI":"10.1212\/NXI.0000000000001153"},{"issue":"2","key":"1875_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/jpn.JPN_185_16","volume":"12","author":"M Barbagallo","year":"2017","unstructured":"Barbagallo M, Vitaliti G, Pavone P, Romano C, Lubrano R, Falsaperla R. Pediatric Autoimmune Encephalitis. J Pediatr Neurosci. 2017;12(2):130\u20134.","journal-title":"J Pediatr Neurosci"},{"issue":"1\u20132","key":"1875_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.canlet.2005.01.051","volume":"228","author":"KK Matthay","year":"2005","unstructured":"Matthay KK, Blaes F, Hero B, Plantaz D, De Alarcon P, Mitchell WG, et al. Opsoclonus Myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228(1\u20132):275\u201382.","journal-title":"Cancer Lett"},{"issue":"2","key":"1875_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1176\/jnp.2006.18.2.239","volume":"18","author":"SB Turkel","year":"2006","unstructured":"Turkel SB, Brumm VL, Mitchell WG, Tavare CJ. Mood and behavioral dysfunction with opsoclonus-myoclonus ataxia. J Neuropsychiatry Clin Neurosci. 2006;18(2):239\u201341.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1875_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejpn.2022.07.002","volume":"40","author":"S Urtiaga Valle","year":"2022","unstructured":"Urtiaga Valle S, Souvannanorath S, Leboucq N, Haouy S, Rivier F, Roubertie A, et al. Monocentric retrospective clinical outcome in a group of 13 patients with opsoclonus myoclonus syndrome, proposal of diagnostic algorithm and review of the literature. Eur J Paediatr Neurol EJPN off J Eur Paediatr Neurol Soc. 2022;40:18\u201327.","journal-title":"Eur J Paediatr Neurol EJPN off J Eur Paediatr Neurol Soc"},{"issue":"1","key":"1875_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12920-023-01474-2","volume":"16","author":"M Kessi","year":"2023","unstructured":"Kessi M, Chen B, Shan L-D, Wang Y, Yang L, Yin F, et al. Genotype-phenotype correlations of STXBP1 pathogenic variants and the treatment choices for STXBP1-related disorders in China. BMC Med Genomics. 2023;16(1):46.","journal-title":"BMC Med Genomics"},{"key":"1875_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fneur.2018.00947","volume":"9","author":"M Kessi","year":"2018","unstructured":"Kessi M, Xiong J, Wu L, Yang L, He F, Chen C, et al. Rare Copy Number variations and predictors in Children with Intellectual Disability and Epilepsy. Front Neurol. 2018;9:947.","journal-title":"Front Neurol"},{"key":"1875_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3389\/fneur.2017.00468","volume":"8","author":"MR Pranzatelli","year":"2017","unstructured":"Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic features of 389 children with Opsoclonus-Myoclonus Syndrome: a cross-sectional study. Front Neurol. 2017;8:468.","journal-title":"Front Neurol"},{"key":"1875_CR12","doi-asserted-by":"publisher","first-page":"744041","DOI":"10.3389\/fneur.2021.744041","volume":"12","author":"H Zhu","year":"2021","unstructured":"Zhu H, Wu W, Chen L, Hou C, Zeng Y, Tian Y, et al. Clinical analysis of Pediatric Opsoclonus-Myoclonus Syndrome in one of the National Children\u2019s Medical Center in China. Front Neurol. 2021;12:744041.","journal-title":"Front Neurol"},{"issue":"2","key":"1875_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nrl.2020.04.025","volume":"38","author":"V Cantar\u00edn-Extremera","year":"2023","unstructured":"Cantar\u00edn-Extremera V, Jim\u00e9nez-Legido M, Aguilera-Albesa S, Hedrera-Fern\u00e1ndez A, Arrabal-Fern\u00e1ndez L, Gorr\u00eda-Redondo N, et al. Opsoclonus-Myoclonus syndrome: clinical characteristics, therapeutic considerations, and prognostic factors in a Spanish paediatric cohort. Neurologia. 2023;38(2):93\u2013105.","journal-title":"Neurologia"},{"issue":"3","key":"1875_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.21037\/tp-21-519","volume":"11","author":"Q Sun","year":"2022","unstructured":"Sun Q, Wang Y, Xie Y, Wu P, Li S, Zhao W. Long-term neurological outcomes of children with neuroblastoma with opsoclonus-myoclonus syndrome. Transl Pediatr. 2022;11(3):368\u201374.","journal-title":"Transl Pediatr"},{"issue":"8","key":"1875_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/archdischild-2018-315487","volume":"104","author":"G Garone","year":"2019","unstructured":"Garone G, Reale A, Vanacore N, Parisi P, Bondone C, Suppiej A, et al. Acute ataxia in paediatric emergency departments: a multicentre Italian study. Arch Dis Child. 2019;104(8):768\u201374.","journal-title":"Arch Dis Child"},{"key":"1875_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pediatrneurol.2017.03.011","volume":"72","author":"A Galstyan","year":"2017","unstructured":"Galstyan A, Wilbur C, Selby K, Hukin J. Opsoclonus-Myoclonus Syndrome: a new era of Improved Prognosis? Pediatr Neurol. 2017;72:65\u20139.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"1875_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejpn.2009.12.005","volume":"14","author":"P Krug","year":"2010","unstructured":"Krug P, Schleiermacher G, Michon J, Valteau-Couanet D, Brisse H, Peuchmaur M, et al. Opsoclonus-Myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol EJPN off J Eur Paediatr Neurol Soc. 2010;14(5):400\u20139.","journal-title":"Eur J Paediatr Neurol EJPN off J Eur Paediatr Neurol Soc"},{"issue":"8","key":"1875_CR18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1177\/0883073814549581","volume":"30","author":"WG Mitchell","year":"2015","unstructured":"Mitchell WG, Wooten AA, O\u2019Neil SH, Rodriguez JG, Cruz RE, Wittern R. Effect of increased immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). J Child Neurol. 2015;30(8):976\u201382.","journal-title":"J Child Neurol"},{"key":"1875_CR19","doi-asserted-by":"crossref","unstructured":"Mizia-Malarz A, Stolpa W, Sobol-Milejska G. The treatment of Opsoclonus-Myoclonus Syndrome secondary to neuroblastic tumours-single-centre experience and literature review. Med (Kaunas). 2020;56(8).","DOI":"10.3390\/medicina56080412"},{"issue":"3","key":"1875_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/aian.AIAN_101_18","volume":"22","author":"K Muthusamy","year":"2019","unstructured":"Muthusamy K, Thomas M, Yoganathan S, Sudhakar SV. Clinical Profile, Prognostic indicators, and therapeutic outcomes of Pediatric Opsoclonus-Myoclonus-Ataxia Syndrome: a single-center experience from South India. Ann Indian Acad Neurol. 2019;22(3):295\u2013301.","journal-title":"Ann Indian Acad Neurol"},{"issue":"5 Pt 1","key":"1875_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0022-3476(06)80167-8","volume":"125","author":"PS Koh","year":"1994","unstructured":"Koh PS, Raffensperger JG, Berry S, Larsen MB, Johnstone HS, Chou P, et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr. 1994;125(5 Pt 1):712\u20136.","journal-title":"J Pediatr"},{"issue":"3","key":"1875_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF01953945","volume":"155","author":"KR Pohl","year":"1996","unstructured":"Pohl KR, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr. 1996;155(3):237\u201344.","journal-title":"Eur J Pediatr"},{"issue":"12","key":"1875_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1111\/dmcn.14628","volume":"62","author":"A Sheridan","year":"2020","unstructured":"Sheridan A, Kapur K, Pinard F, Dietrich Alber F, Camposano S, Pike MG, et al. IQ predictors in pediatric opsoclonus myoclonus syndrome: a large international cohort study. Dev Med Child Neurol. 2020;62(12):1444\u20139.","journal-title":"Dev Med Child Neurol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-01875-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:13:17Z","timestamp":1738948397000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-01875-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-01875-2","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study including all methods adhered to the tenets of the Declaration of Helsinki and received approval from the Institutional Review Board and Research Ethics Committee of Xiangya Hospital, Central South University, Changsha, Hunan. The ethical approval number 202310892 was obtained on 19th October 2023. Written consents were obtained from the parents\/guardians of the subjects, which were approved by the Institutional Ethics Committee of Xiangya Hospital, Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents for publication of clinical details and clinical images were obtained from participants or the parents of the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors has any conflict of interest to disclose. The manuscript has been read and approved by all the authors, the requirements for authorship as stated in the journal guideline have been met, and each author believes that the manuscript represents honest work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}